Clinical Trials in Pisa, Italy
5 recruiting
Showing 1–18 of 18 trials
Recruiting
Not Applicable
Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC
Fondazione del Piemonte per l'Oncologia160 enrolled6 locationsNCT07479277
Recruiting
Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
AstraZeneca630 enrolled99 locationsNCT05061550
Recruiting
Phase 3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Prostate Cancer
AstraZeneca700 enrolled328 locationsNCT06952803
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
AstraZeneca830 enrolled288 locationsNCT06868277
Recruiting
Phase 1Phase 2
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Breast CancerSolid Tumors, Adult
Eli Lilly and Company720 enrolled67 locationsNCT05768139
Recruiting
Phase 3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Small Cell Lung CancerLimited Stage Small Cell Lung Cancer
Amgen400 enrolled204 locationsNCT06117774
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
AstraZeneca4,300 enrolled727 locationsNCT05774951
Recruiting
stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database
Breast CancerOligometastasis
Istituto Clinico Humanitas300 enrolled28 locationsNCT07397585
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
Sentinel Lymph Node Biopsy (SLNB)ALNDTargeted Axillary Dissection (TAD)
European Institute of Oncology150 enrolled14 locationsNCT07278726
Recruiting
Phase 1Phase 2
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Breast CancerMetastatic Breast Cancer
Stemline Therapeutics, Inc.435 enrolled118 locationsNCT05563220
Recruiting
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Metastatic Breast Cancer
European Institute of Oncology1,000 enrolled37 locationsNCT06994377
Recruiting
Phase 3
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Breast Cancer
Greenwich LifeSciences, Inc.750 enrolled161 locationsNCT05232916
Recruiting
Not Applicable
Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy
Breast CancerFatigue
Pharmanutra S.p.a.92 enrolled5 locationsNCT06137833
Recruiting
Phase 3
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
European Organisation for Research and Treatment of Cancer - EORTC220 enrolled94 locationsNCT05512364
Recruiting
Not Applicable
Safety and Performance of REGENERA Breast Implant in Women Affected by Malignant Breast Lesion Treated by Lumpectomy
Mastectomy, SegmentalBreast Neoplasm Malignant Female
Tensive SRL92 enrolled3 locationsNCT05941299
Recruiting
PREgnancy and FERtility Registry
Breast NeoplasmsPregnancyFertility Preservation
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy1,000 enrolled23 locationsNCT02895165